CoChat

Characterization of MK-4166, a Clinical Agonistic Antibody That Targets Human GITR and Inhibits the Generation and Suppressive Effects of T Regulatory Cells

Sukumar, Selvakumar, Wilson, Douglas C., Yu, Ying, Wong, Jerelyn, Naravula, Saraswathi, Ermakov, Grigori, Riener, Romina, Bhagwat, Bhagyashree, Necheva, Antoaneta S., Grein, Jeff, Churakova, Tatyana, Mangadu, Ruban, Georgiev, Peter, Manfra, Denise, Pinheiro, Elaine M., Sriram, Venkataraman, Bailey, Wendy J., Herzyk, Danuta, McClanahan, Terrill K., Willingham, Aarron, Beebe, Amy M., Sadekova, Svetlana · 2017 · Cancer Research
Cited by 61

The DOI matches its Crossref record.

Abstract

GITR is a T-cell costimulatory receptor that enhances cellular and humoral immunity. The agonist anti-mouse GITR antibody DTA-1 has demonstrated efficacy in murine models of cancer primarily by attenuation of Treg-mediated immune suppression, but the translatability to human GITR biology has not been fully explored. Here, we report the potential utility of MK-4166, a humanized GITR mAb selected to bind to an epitope analogous to the DTA-1 epitope, which enhances the proliferation of both naïve and tumor-infiltrating T lymphocytes (TIL). We also investigated the role of GITR agonism in human antitumor immune responses and report here the preclinical characterization and toxicity assessment of MK-4166, which is currently being evaluated in a phase I clinical study. Expression of human GITR was comparable with that of mouse GITR in tumor-infiltrating Tregs despite being drastically lower in other human TILs and in many human peripheral blood populations. MK-4166 decreased induction and suppressive effects of Tregs in vitro. In human TIL cultures, MK-4166 induced phosphorylation of NFκB and increased expression of dual specificity phosphatase 6 (DUSP6), indicating that MK-4166 activated downstream NFκB and Erk signaling pathways. Furthermore, MK-4166 downregulated FOXP3 mRNA in human tumor infiltrating Tregs, suggesting that, in addition to enhancing the activation of TILs, MK-4166 may attenuate the Treg-mediated suppressive tumor microenvironment. Cancer Res; 77(16); 4378–88. ©2017 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-16-1439

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 61

Metadata

Authors
Sukumar, S., Wilson, D. C., Yu, Y., Wong, J., Naravula, S., Ermakov, G., Riener, R., Bhagwat, B., Necheva, A. S., Grein, J., Churakova, T., Mangadu, R., Georgiev, P., Manfra, D., Pinheiro, E. M., Sriram, V., Bailey, W. J., Herzyk, D., McClanahan, T. K., Willingham, A., Beebe, A. M., & Sadekova, S.
Venue
Cancer Research
Published
2017-08-14
Volume
77
Issue
16
Pages
4378-4388
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2626962960
Cited by
61
References
0
FWCI
2.51
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Characterization of MK-4166, a Clinical Agonistic Antibody That Targets Human GITR and Inhibits the Generation and Suppressive Effects of T Regulatory Cells. https://app.cochat.ai/papers/10.1158/0008-5472.can-16-1439
The paper
Sukumar, S., Wilson, D. C., Yu, Y., Wong, J., Naravula, S., Ermakov, G., Riener, R., Bhagwat, B., Necheva, A. S., Grein, J., Churakova, T., Mangadu, R., Georgiev, P., Manfra, D., Pinheiro, E. M., Sriram, V., Bailey, W. J., Herzyk, D., McClanahan, T. K., . . . Sadekova, S. (2017). Characterization of MK-4166, a Clinical Agonistic Antibody That Targets Human GITR and Inhibits the Generation and Suppressive Effects of T Regulatory Cells. Cancer Research. https://doi.org/10.1158/0008-5472.can-16-1439

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.